Photobiomodulation mitigates chondrocyte catabolism in osteoarthritis by modulating macrophage M1 polarization through the IL-6/JAK/STAT pathway Authors: Haiming Wang, Wenhua Ning, Yiying Liu, Jing Nie, Shenao Du, Haowei Zhang Published: 2025 ABSTRACT AbstractBackgroundOsteoarthritis (OA) is a prevalent degenerative joint disease characterized by cartilage destruction and synovial inflammation, with macrophage-mediated immune dysregulation playing a pivotal role. Photobiomodulation (PBM), a non-invasive light therapy, has shown promise in alleviating OA by modulating macrophage polarization. However, the precise underlying molecular mechanisms remain unclear.MethodsWe integrated single-cell and bulk RNA sequencing data from the Gene Expression Omnibus (GEO) database to identify key cellular players and pathways in OA. The functional effects of PBM were assessed in vitro using ATDC5 chondrogenic cell and macrophage co-cultures, and in vivo using the DMM-induced OA murine model with macrophage depletion and PBM intervention.ResultsAnalysis of single-cell and bulk RNA sequencing data revealed a strong correlation between macrophage and OA, highlighting the importance of the IL-6/JAK/STAT signalling pathway in the regulation of synovial macrophage and OA progression. In vitro experiments demonstrated that PBM intervention enhanced chondrocyte proliferation while suppressing catabolic activity and inhibiting macrophage polarization towards a pro-inflammatory phenotype through the IL-6/JAK/STAT pathway. In vivo experiments further confirmed that PBM intervention attenuated articular cartilage degradation and synovial hyperplasia via IL-6/JAK/STAT-dependent modulation of macrophage polarization.ConclusionsOur study demonstrated that PBM intervention mitigated OA progression by regulating macrophage polarization through the IL-6/JAK/STAT pathway, emphasizing the therapeutic potential of immune modulation in OA management. These findings provide a mechanistic basis for PBM intervention as a nonpharmacological strategy for joint degeneration.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13018-025-06506-4.Keywords: Photobiomodulation, Osteoarthritis, Chondrocyte, Macrophage Introduction Osteoarthritis (OA) is a common disabling disease affecting millions of individuals globally [1]. This condition is characterized by progressive degeneration of articular cartilage and involves a multifactorial interplay integrating mechanical stress, metabolic abnormalities, and immune dysregulation [2–4]. Chronic activation of the immune system is not only a consequence of the joint damage, but also a key factor driving the progression of OA [5]. Despite OA’s widespread prevalence and significant impact on quality of life, effective therapeutic options remain limited [6]. A better understanding of how the immune system drives the pathology of OA is crucial for identifying novel therapeutic strategies. The major immune cells involved in cartilage destruction and repair include macrophages, osteoclasts, T cells, B cells, natural killer cells and dendritic cells [7, 8]. Among these cells, macrophages represent one of the most abundant populations in the joint and exhibit significant heterogeneity in both phenotype and function under different polarization processes [9, 10]. M1 macrophages are generally considered pro-inflammatory cells, while M2 macrophages are anti-inflammatory cells, and an imbalance between M1 macrophages and M2 macrophages can lead to chronic low-grade inflammation, which has recently become a popular research topic in relation to a wide variety of musculoskeletal disorders, including OA, tendinopathy, osteonecrosis and spinal cord injury [11–16]. Cartilage damage can trigger macrophage infiltration into synovial tissue and joint fluid, resulting in elevated secretion of pro-inflammatory cytokines, including IL-1β, TNF-α, IL-6, and IL-23, which contribute to OA pathogenesis [17, 18]. In addition, macrophages recruit other immune cells by phagocytosing cell debris and secreting inflammatory mediators, thereby accelerating the clearance of damaged tissue [19]. Photobiomodulation (PBM) uses non-ionizing light sources such as lasers, light-emitting diodes (LEDs) or broadband light to generate red or near-infrared light for therapeutic applications [20]. Because the output power of PBM is typically less than 500 mW, it does not increase the temperature of the targeted tissue, making PBM an ideal treatment option for various conditions, especially those involving inflammation or those requiring stimulation of tissue growth and repair [21]. PBM has been demonstrated to regulate macrophage polarization [22–25], suppressing M1 polarization and pro-inflammatory cytokine expression while promoting M2 polarization [26]. Clinical studies have reported PBM-mediated improvement in clinical outcomes is accompanied by a reduction in the levels of macrophage inflammatory protein-1α (MIP-1α) [27]. To further clarify the role of PBM in OA, we explored the effects of PBM-regulated macrophage polarization on the catabolism of chondrocyte and the underlying mechanisms. This study aimed to provide new insights into potential therapeutic targets for the prevention and treatment of OA. Methods Analysis of datasets from the GEO database The Gene Expression Omnibus (GEO) is an open genomics database collecting high-throughput gene expression data. We used the keywords “Synovial tissue” and “Synovium” to search datasets in the GEO, and seven datasets were collected (GSE176308, GSE3698, GSE77298, GSE82107, GSE55235, GSE55457 and GSE55584). The flowchart of bioinformatics analysis is shown in Fig. 1, and the detailed procedure is described in the Supplementary Material 1. Flowchart of bioinformatics analysis, drawn by Figdraw Cell lines and cell culture The ATDC5 chondrogenic cell line and RAW264.7 macrophage cell line were obtained from the American Type Culture Collection (ATCC, USA). The ATDC5 chondrogenic cell line is an excellent cell model for in vitro chondrocyte research that exhibits chondrogenic proliferation, hypertrophic differentiation, and matrix mineralization upon prolonged incubation [28]. The ATDC5 chondrogenic cells were cultured in DMEM/F12 (Procell, China) with 10% foetal bovine serum (FBS, Procell, China) at 37 °C and 5% CO2. To induce chondrogenic differentiation, ATDC5 chondrogenic cells were treated with 1% insulin-transferrin-selenium (ITS-G, Procell, China), and the concentration of FBS was reduced from 10% to 5% for a period of 14 days (D). The RAW264.7 cells have been previously described as an appropriate model of macrophages, as the cells are well characterized in terms of macrophage-mediated immune, metabolic and phagocytic functions [29]. The RAW264.7 cells were cultured in DMEM (Procell, China) with 10% FBS at 37 °C and 5% CO2. Cell treatment The ATDC5 chondrogenic cells were cultured in the lower chamber of a Transwell system (Corning, USA) and induced to differentiate into chondrocytes for 14D. Meanwhile, the RAW 264.7 cells were individually added to the upper chamber of a Transwell system and treated with 100 ng/mL LPS and 30 ng/mL IFN-γ for 24 h (H) to induce M1 polarization. Then, to investigate the effect of M1 macrophages on the chondrocytes, the upper chamber containing M1 macrophages was placed onto the lower chamber with chondrocytes differentiated for 14D and co-cultured for 24 H. Chondrocytes treated with IL-1β (10 ng/mL) for 24 H served as the positive control, whereas chondrocytes cultured alone (without macrophage co-culture or IL-1β stimulation) served as the negative control. Animal models All experimental procedures involving animals were conducted in accordance with the Ethics Committee of Zhengzhou University (ZZU-LAC20220902[09]). Male C57BL/6 mice (10–12 weeks old) were purchased from the Experimental Animal Centre of Zhengzhou University and housed under a 12-hour light/dark cycle at 25 ± 2 °C and 50 ± 5% humidity with ad libitum access to food and water. These mice underwent sham surgery or destabilization of the medial meniscus (DMM) surgery (establishing models of post-traumatic OA) [30]. The mice were randomly assigned to undergo either sham surgery (n = 10) or DMM surgery (n = 50) using a computer-based random number generator (RAND function in Microsoft Excel). For the sham surgery (n = 10), an arthrotomy without transecting the medial meniscotibial ligament was performed. DMM surgery (n = 50) was performed as previously reported [31]. At 4 weeks post-surgery, after ensuring that no mouse died prematurely due to the DMM surgery, the DMM-operated mice were further randomly assigned to five experimental groups (n = 10 per group) using the same randomization method, and housed in their respective groups for a period of 4 weeks that served both for acclimatization to reduce stress and aggressive interactions, and for the continued development of the OA pathology. Interventions were subsequently initiated at 8 weeks post-surgery and continued for 4 weeks until the endpoint. The groups were as follows: (a) sham group, (b) OA group, (c) OA group treated with intra-articular injection of control liposomes (CTRL Lips, liposomes encapsulating PBS, Yeasen, China, Cat. No. 40338ES08, 6 µL per injection) once weekly for 4 weeks (OA + CTRL Lips group), (d) OA group treated with intra-articular injection of clodronate liposomes (CLD Lips, Yeasen, China, Cat. No. 40337ES08, 5 mg/mL clodronate, as selective eliminators of macrophages [32], 6 µL per injection) once weekly for 4 weeks (OA + CLD Lips group), (e) OA group treated with PBM interventions six times weekly for 4 weeks (OA + PBM group), (f) OA group treated with intra-articular injection of CLD Lips (6 µL per injection) once weekly for 4 weeks and PBM interventions six times weekly for 4 weeks (OA + CLD Lips + PBM group). All mice were sacrificed at 12 weeks after the sham surgery or DMM surgery and knee joints were obtained for subsequent experiments. All animals survived until the experimental endpoint of 12 weeks after surgery, and no exclusions were made due to death or other diseases. All animal experiments comply with the ARRIVE guidelines and were conducted in strict accordance with the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe. All surgical procedures were performed under appropriate anaesthesia, and every effort was made to minimize animal suffering. Table 1Table of animal experiment groupingGroupDMM SurgeryInjectionContent of InjectionDose of InjectionFrequency of InjectionPBM interventionSham Group------OA Group√-----OA + CTRL Lips Group√Intra-articular InjectionCTRL Lips6 µL1 time/week for 4 weeks-OA + CLD Lips Group√Intra-articular injectionCLD Lips6 µL1 time/week for 4 weeks-OA + PBM Group√----6 times/week for 4 weeksOA + CLD Lips + PBM Group√Intra-articular injectionCLD Lips6 µL1 time/week for 4 weeks6 times/week for 4 weeks Table of animal experiment grouping Photobiomodulation intervention An 808 nm laser (Blueprint, China) was used for PBM intervention in both in vitro and in vivo experiments. In vitro experiments: PBM intervention was performed in an ultraclean environment with the following parameters: power output of 27 mW, beam spot size at target of 4.5 cm², total energy of 11.34 J, exposure duration of 7 min, and energy density of 2.52 J/cm², applied in continuous mode with direct contact with the plate lid. In vivo experiments: Mice were anaesthetized, and the right knee joints were shaved, cleaned, and immobilized during the intervention period. PBM was applied to two points (medial and lateral) of the knee joint interline with the following parameters: power output of 50 mW, beam spot size at target of 0.2 cm², total energy of 15 J/point, exposure duration of 5 min/point, and energy density of 75 J/cm², applied in continuous mode. The intervention was applied between 7 am and 7 pm, and the testing order was randomized daily, with each animal tested at a different time each test day. The parameters and settings of the device were selected based on pre-experiments and previous reports [33, 34]. The wavelength of 808 nm was chosen for its superior tissue penetration within the near-infrared window, enabling effective reach to deep joint structures [34, 35]. An energy density of 2.52 J/cm² for the in vitro experiments and 75 J/cm² for the in vivo experiments was employed as it falls within the established therapeutic range known to elicit significant anti-inflammatory and cytomodulatory effects without inducing cellular damage, adhering to the biphasic dose-response principle of PBM [33, 36]. The power output was configured to deliver a low irradiance, ensuring a sufficient intervention time to achieve the desired energy dose while avoiding thermal effects, thereby enhancing the direct applicability of our findings to potential human therapies [37]. Western blotting The harvested cells or animal tissue were washed with PBS and lysed on ice using radioimmunoprecipitation assay (RIPA) buffer (Epizyme, China) supplemented 1% phenylmethanesulfonyl fluoride (Epizyme, China). The lysates were centrifuged to remove insoluble debris, and the supernatant was collected. The protein concentration was determined using a BCA protein assay kit (Epizyme, China). Equal amounts of protein were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS‒PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, USA). The membranes were blocked with 5% skim milk for 1 H at room temperature and then incubated overnight at 4 °C with the following primary antibodies diluted at 1:1000: anti-IL-6 (Cat. No. 12153, Cell Signaling Technology, USA), anti-JAK1 (Cat. No. 3344, Cell Signaling Technology, USA), anti-JAK2 (Cat. No. 3230, Cell Signaling Technology, USA), anti-STAT3 (Cat. No. 9139, Cell Signaling Technology, USA), anti-phospho-STAT3 (P-STAT3; Cat. No. 9145, Cell Signaling Technology, USA), anti-MMP13 (Cat. No. 18165-1-AP, Proteintech, China), anti-ADAMTS5 (Cat. No. DF13268, Affinity Biosciences, USA), anti-COL2A1 (Cat. No. ab307674, Abcam, UK), anti-ACAN (Cat. No. DF7561, Affinity Biosciences, USA), and anti-β-actin (Cat. No. 66009-1-IG, Proteintech, China). After washing, the membranes were incubated for 1 H at room temperature with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Cat. No. A21020, Abbkine, China; 1:10,000) or HRP-conjugated goat anti-mouse IgG (Cat. No. A21010, Abbkine, China; 1:10,000). Protein bands were visualized using Amersham Imager 600 (General Electric, USA). Tissue decalcification, processing and sectioning Following euthanasia, the knee joints were dissected to preserve all intra-articular structures after disarticulation at the hip. Following 48 H fixation with 4% PFA, tissue samples were placed in perforated tubes or embedding cassettes and immersed in 0.5 M EDTA decalcification solution (pH 7.4, Servicebio, China) under continuous agitation using an orbital shaker (110–120 rpm) at 28 °C. The decalcification solution was replaced every 48–72 h. The decalcification endpoint was determined by needle puncture testing. Upon complete decalcification, the samples were rinsed under running water and subjected to graded ethanol dehydration (75% to 100%), cleared in xylene, and infiltrated with paraffin. Sections were cut at 4 μm thickness using a rotary microtome, floated on a 40 °C water bath, mounted onto glass slides, and dried at 60 °C. The slides were then stored at room temperature for subsequent staining. Immunohistochemistry and immunofluorescence staining Sections were deparaffinized in xylene (two changes, 10 min each) and rehydrated through a graded ethanol series (100%, 95%, 85%, and 75%; 5 min per concentration). Heat-induced antigen retrieval was performed by incubating the slides in citrate buffer (10 mM, pH 6.0) at 95 °C for 20 min using a steam heater. After cooling to room temperature, the slides were washed gently with PBS buffer. Subsequently, nonspecific binding sites were blocked with 10% normal goat serum (Servicebio, China) for 30 min at room temperature. For immunohistochemistry (IHC), sections were incubated overnight at 4 °C with the following primary antibodies diluted at 1:100: anti-MMP13 (Cat. No. 18165-1-AP, Proteintech, China), anti-ADAMTS5 (Cat. No. DF13268, Affinity Biosciences, USA), anti-IL-6 (Cat. No. 12153, Cell Signaling Technology, USA), anti-JAK1 (Cat. No. 3344, Cell Signaling Technology, USA), anti-JAK2 (Cat. No. 3230, Cell Signaling Technology, USA), and anti-STAT3 (Cat. No. 10253-2-AP, Proteintech, China). After washing with PBS buffer, the sections were incubated with goat anti-rabbit IgG polymer (Cat. No. PV-6000, ZSGB-BIO, China) for 1 H at room temperature. Immunoreactivity was visualized using a DAB Peroxidase (HRP) Substrate Kit (ZSGB-BIO, China), followed by counterstaining with haematoxylin, dehydration, and mounting. For single-labelled immunofluorescence (IF), sections were incubated overnight at 4 °C in a humidified chamber with rabbit anti-F4/80 (Cat. No. A08751, rabbit polyclonal, Bosterbio, USA) diluted 1:100. For dual-labelled IF, sections were first blocked and then incubated with anti-CD86 antibody (Cat. No. A00220-4, rabbit polyclonal, Bosterbio, USA) diluted 1:100 overnight at 4 °C. After washing with PBS buffer, tyramide signal amplification was performed using a commercial TSA kit (Cat. No. AFIHC023, AiFang Biological, China) according to the manufacturer’s instructions. Briefly, sections were incubated with HRP-conjugated secondary antibody for 1 H at room temperature, followed by incubation with FITC-Tyramide working solution for 5–10 min. To enable dual labelling, antibody complexes were removed by a second heat-induced antigen retrieval step in citrate buffer (95 °C, 20 min). After cooling and blocking, sections were incubated overnight at 4 °C with the second primary antibody, anti-CD206 antibody (Cat. No. A02285-2, rabbit polyclonal, Bosterbio, USA) diluted 1:100. The sections were then incubated with HRP-conjugated secondary antibody for 1 H at room temperature, followed by Cy3-Tyramide working solution for 5–10 min. Finally, the sections were mounted with an anti-fade mounting medium containing DAPI (Solarbio, China). Image acquisition was performed on Nikon Eclipse Ci-L microscope (Nikon, Japan) at 40 × (4X objective and 10X eyepiece) and 100 × (10X objective and 10X eyepiece) magnifications. A DS-Fi3 camera and NIS-Elements BR software were used to capture images under consistent exposure settings. RNA interference (siRNA) siRNA transfection was conducted using riboFECT™ CP reagent and buffer (Ribobio, China). ATDC5 chondrogenic cells were predifferentiated with 1% ITS-G and 5% FBS for 14D prior to transfection. Scrambled control or IL-6 siRNA duplexes were diluted in riboFECT™ CP buffer and incubated with the riboFECT™ CP reagent for 15 min. The mixture was then added to the cells cultured in DMEM/F12 supplemented with 5% FBS and 1% ITS-G for further chondrogenic differentiation. Next, the cells were collected for follow-up experiments in accordance with the experimental requirements. The siRNAs target sequences were as follows: si-IL-6#1, sense, 5’-GAGAGAUACAGAAACUCUATT-3’, antisense, 5’-UAGAGUUUCUGUAUCUCUCTT-3’; si-IL-6#2, sense, 5’-CGAUGAUGCACUUGCAGAATT-3’, antisense, 5’-UUCUGCAAGUGCAUCAUCGTT-3’. ELISA assay Cell culture supernatants were collected and centrifuged at 1000 × g for 20 min. Thereafter, specific protein quantification was performed by ELISA according to manufacturer guidelines (Ruixin biotect, China). Briefly, standards and samples were prepared in dilution buffer and added to the precoated plate (100 µL/well), with seven standard concentrations and appropriate blanks. After adding biotinylated detection antibody (50 µL/well), the plate was sealed and incubated for 2 H at room temperature. Then, the plate was washed five times with 300 µL wash buffer per well, followed by the addition of streptavidin-HRP conjugate (100 µL/well) and incubation for 30 min. After repeating the washing step, TMB substrate (90 µL/well) was added for colour development at room temperature for 10–30 min protected from light. The reaction was stopped with stop solution (50 µL/well) when clear blue gradient appeared in the standard wells. The absorbance was measured at 450 nm and 630 nm within 10 min after termination. Final OD values were calculated by subtracting the 630 nm readings from the 450 nm measurements. All samples were analysed in duplicate, and the sample concentrations were determined by interpolation from the standard curve. CCK-8 assay The CCK-8 assay was performed using a CCK-8 kit (Abbkine, China). The cells were plated at 1,000 cells per well. A mixture of 10 µl CCK-8 reagent and 90 µl of medium was added to each well. After incubating at 37 °C for 2 H in a humidified incubator with 5% CO2, the proliferative ability of the cells was measured at a wavelength of 450 nm using a microplate reader. Micro-CT imaging and analysis After euthanizing the mice, their knee joints were harvested and fixed in 4% PFA for 48 H. The samples were scanned using a high-resolution micro-CT system (VNC-102, Pingsheng Health Care, China) with the following acquisition parameters: continuous scanning mode, tube voltage 90 kV, tube current 0.09 mA, source-to-detector distance 540 mm, source-to-object distance 60 mm, frame rate 20/s, total frames 10,000, reconstruction type FDK, isotropic voxel size 26 μm, and a global CT threshold of 1205. The raw data were reconstructed using Recon software (Pingsheng Health Care, China) to generate three-dimensional images. A standardized region of interest (ROI) was defined extending from the tibial growth plate to the tibial plateau. Quantitative morphometric analysis was performed using Avatar software (Pingsheng Health Care, China). Key parameters evaluated included bone volume fraction (BV/TV, %) and trabecular separation (Tb.Sp, mm). All scans and analyses were conducted under consistent conditions to ensure comparability across samples. Histological analysis The haematoxylin and eosin (H&E) staining kits and Safranin O-Fast Green staining kit were obtained from Solarbio (Solarbio, China). For H&E staining, sections were stained with haematoxylin for 10 min, differentiated in differentiation solution for 10 s, treated with bluing solution for 2 min, and counterstained with eosin Y for 5 min before dehydration and mounting. For Safranin O-Fast Green staining, sections were stain with weigert hematoxylin working solution for 3–5 min and then differentiated with acid differentiation solution for 15s. Subsequently sections stained with fast green solution for 1–2 min, differentiated in weak acid solution for 10 s, and counterstained with safranin O solution for 1–2 min. After rapid dehydration, sections were mounted with neutral balsam. The severity of OA was assessed on histologic sections of the medial tibial plateau by two independent, blinded observers using both the OARSI (0 to 6) and Mankin (0 to 14) scoring systems, which showed excellent inter-observer agreement (ICC >0.9). Consequently, the final OARSI and Mankin score for each sample was defined as the mean of the two scores for all statistical analyses [30, 38]. Statistical analysis All the statistical analyses were performed using GraphPad Prism version 10.2.3 (GraphPad Software, La Jolla, CA, USA). Continuous data are presented as the mean ± standard deviation (SD). The normality of data distribution within each experimental group was assessed using the Shapiro-Wilk test. Homogeneity of variance was assessed using the F test for two-group comparisons and the Brown-Forsythe test for multi-group comparisons. For two-group comparisons, Student’s t test was applied when the variances were equal, whereas Welch’s t test was used when the variances were unequal. For multi-group comparisons, one-way ANOVA followed by Tukey’s honestly significant difference (HSD) post hoc test was employed when variances were homogeneous, whereas Welch’s ANOVA with the Games-Howell post hoc test was utilized when variances were heterogeneous. A P value of less than 0.05 was considered to indicate statistical significance. Results Macrophages and IL-6/JAK/STAT pathway correlate with OA In the single-cell RNA-sequencing (scRNA-seq) data analysis, 17,470 cells from synovial tissue of 8 patients (4 early OA samples and 4 end-stage OA samples) were included after quality filtering (Fig. S1A, S1B). Using well-established marker genes, seven distinct cell clusters were identified: medullary cell, fibrocartilage chondrocyte, fibroblast, macrophage, monocyte, natural killer T cell, and M1 macrophage (Fig. 2A). Analysis of cell proportions in samples from 4 early OA and 4 end-stage OA revealed that fibrocartilage chondrocytes and fibroblasts collectively made up more than 50% of the total cells in those samples. The key difference was that the proportions of M1 macrophages and monocytes were higher in early OA samples compared with end-stage OA samples. Conversely, the proportion of macrophages was significantly higher in end-stage OA samples than in early OA samples (Fig. 2B). We next performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of marker genes and used the results to plot column charts. GO enrichment revealed the complex biological functions and regulatory mechanisms of cells in energy metabolism, substance transport, gene expression, and stress response (Fig. 2C). The most significantly enriched KEGG pathways included oxidative phosphorylation, diabetic cardiomyopathy, chemical carcinogenesis-reactive oxygen species, thermogenesis and endocytosis, highlighting the central roles of oxidative stress and metabolic dysregulation in cellular processes and disease (Fig. 2D). Notably, macrophage subpopulations were closely linked to these pathways, and numerous studies have highlighted their critical roles in oxidative stress, inflammation, and immune regulation [39–41]. These findings underscore the multifaceted functions of macrophages in OA and provide key insights into their molecular mechanisms. ScRNA-seq analysis of early OA and end-stage OA. A Bar graph depicting the percentages of each of the 7 clusters, showing the cell proportion distribution in the different groups. B UMAP plot of the 7 clusters, annotated and coloured by the sample type and clustering. C GO enrichment bar plot of marker genes. D KEGG enrichment bar plot of marker genes We identified 2485 differentially expressed genes (DEGs), with 456 upregulated and 2029 downregulated genes from the bulk RNA sequencing (bulk RNA-seq) of synovial tissues in the normal subject group and OA patient group (Fig. 3A and B). For detailed analysis of protein-protein interaction (PPI) network of DEGs, which involved the extraction of the densest connected regions from the PPI network, we obtained the top 10 hub genes (Fig. 3C and D). GO and KEGG enrichment analyses showed that these genes were primarily involved in Parkinson’s disease, Prion disease, proteasome core complex, cytoplasmic ribonucleoprotein granule, proteasome, growth hormone receptor signalling pathway via JAK-STAT, etc. (Fig. 3E). Among these, the classic inflammatory signalling pathway about OA directly enriched is the “JAK/STAT” pathway [42–44]. The densest connected regions of DEGs from bulk RNA-seq data also included interleukin-6 cytokine family signal transducer (IL-6ST) and janus kinase 1 (JAK1), both related to the IL-6/JAK/STAT pathway. Given that activated macrophages secreted higher concentrations of IL-6 [45], it is speculated that the IL-6/JAK/STAT pathway plays a crucial role in OA associated with macrophages. Bulk RNA-seq analysis of normal group and OA group. A Volcano plot and B heatmap of the DEGs. C The densest connected regions of DEGs from the PPI network; a deeper colour represents a higher degree of connectivity. D Top 10 hub genes of the densest connected regions; a deeper colour indicates higher connectivity values. E GO and KEGG enrichment network The chondrogenic differentiation of ATDC5 chondrogenic cells based on the IL-6/JAK/STAT pathway ATDC5 chondrogenic cells were cultured for 4D, 7D, 14D and 21D, and then assessed using Alcian Blue-Alizarin Red staining to detect proteoglycans and calcified matrix. The staining intensity increased progressively from 4D to 21D (Fig. 4A and B). By 14D, the ATDC5 chondrogenic cells exhibited distinct blue cartilage nodules and red mineralized nodules. At this stage, the protein and mRNA relative expression levels of collagen type II alpha 1 (COL2A1) and aggrecan (ACAN), key anabolic markers related to cartilage, were significantly increased compared to 4D stage (Fig. 4D, F and G). By 21D, the nodules had aggregated into large plaques, and hypertrophic cells dominated the mineralized area. The expression of catabolic makers, matrix metallopeptidase 13 (MMP13) and a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), peaked at 21D, while COL2A1 and ACAN levels decreased compared to 14D (Fig. 4D, F, G, H and I). Based on the morphology and the molecular testing results of cells, we confirmed that the ATDC5 chondrogenic cell line had differentiated into chondrocytes in 14D and underwent cellular hypertrophy and mineralization with increasing time of differentiation in 21D. Differentiation of the ATDC5 chondrogenic cell and IL-6/JAK/STAT pathway activation. A Alcian Blue and Alizarin Red staining at different time points during ATDC5 chondrogenic cell differentiation (n = 4) (staining method presented in Supplementary Material 1). B–C Sum object area of the staining by densitometry analysis (n = 4). D–E The protein levels of COL2A1, ACAN, ADAMTS5, MMP13, IL-6, JAK1, JAK2, STAT3 and P-STAT3 in the ATDC5 chondrogenic cell. β-actin was used as an internal loading control (n = 3). F–M The relative mRNA levels of COL2A1, ACAN, ADAMTS5, MMP13, IL-6, JAK1, JAK2 and STAT3 (n = 3). GAPDH was used as a reference gene (Data are presented as mean ± SD; Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) The expression of key IL-6/JAK/STAT pathway components including IL-6, JAK1, janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3) and phosphorylated signal transducer and activator of transcription 3 (P-STAT3) were detected in ATDC5 chondrogenic cells during differentiation (7D, 14D and 21D), showing differentiation stage-dependent increase in expression (Fig. 4E, J, K, L and M). This trend aligned with the differentiation process observed via Alcian Blue-Alizarin Red staining, and the expression levels of MMP13 and ADAMTS5 during the differentiation of ATDC5 chondrogenic cells from chondrocytes to hypertrophic chondrocytes were greater than those of COL2A1 and ACAN (Fig. 4D, E, F, G, H and I). These findings suggest that the IL-6/JAK/STAT pathway is broadly activated during differentiation and plays a role in the catabolism of chondrocytes. Effects of PBM on chondrocyte and macrophage polarization For the follow-up experiments, we used ATDC5 chondrogenic cells predifferentiated for 14D into chondrocytes. Chondrocytes in the control group exhibited a slow rate of proliferation, whereas PBM significantly promoted cell proliferation after both a single intervention and seven consecutive interventions (Fig. 5A). PBM was applied once every 24 H, and after seven consecutive irradiations from 14D to 21D, the mineralized plaques of chondrocytes were significantly reduced (Fig. 5B, C and D). The effect of PBM intervention on chondrocytes based on the IL-6/JAK/STAT pathway. A Effect of PBM on cell proliferation measured with a CCK-8 assay (n = 5). B Alcian Blue and Alizarin Red staining (n = 4). C–D Sum object area of the staining by densitometry analysis (n = 4). E and F Western blotting and qPCR to determine the expression of IL-6 after transfecting with si-NC, si-IL-6#1 or si-IL-6#2 (n = 3). G Flow chart for macrophages co-culture system operation method, drawn by Figdraw. H and I M1 macrophages were estimated by flow cytometry (n = 3). J The protein levels of MMP13, ADAMTS5, JAK1, JAK2, STAT3, P-STAT3 and β-actin in the chondrocytes after different interventions. β-actin was used as an internal loading control (n = 3). K IL-6 contents were determined via ELISA (n = 4). (Data are presented as mean ± SD; Statistical significance was determined by student’s t-test or one-way ANOVA followed by Tukey’s post-hoc test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) To further investigate whether PBM affects OA pathogenesis by regulating macrophage M1 polarization via the IL-6/JAK/STAT pathway, we conducted several experiments. First, we verified that the expression of the M1 macrophage marker CD86 significantly increased in the LPS + IFN-γ group. In contrast, the LPS + IFN-γ + PBM group showed reduced M1-like polarization of cells after a single PBM intervention (Fig. 5H and I). Then, we used IL-1β to establish a model of OA-like chondrocytes, and compared it with chondrocytes co-cultured with M1 macrophages. It was observed that after being stimulated by IL-1β and co-cultured with M1 macrophages (for 24 H), the protein expression levels of MMP13, ADAMTS5, IL-6, JAK1, JAK2, STAT3 and P-STAT3 increased in chondrocytes (Fig. 5J). Subsequently, IL-1β-induced OA chondrocytes were subjected to various interventional strategies, including PBM intervention, treatment with a JAK inhibitor and transfection with IL-6 siRNA. JAK inhibitor and IL-6 siRNA significantly downregulated the expression levels of catabolic makers and the key molecules of the IL-6/JAK/STAT pathway, confirming the ability of IL-6/JAK/STAT in attenuating inflammatory catabolism, while PBM intervention similarly suppressed catabolism in chondrocytes and IL-6/JAK/STAT pathway activation (Fig. 5J, S2A-E). Notably, the combination of PBM and a JAK inhibitor or PBM and IL-6 siRNA exhibited enhanced efficacy in inhibiting the catabolism of chondrocytes, indicating that PBM may modulate catabolism through both JAK-dependent and JAK-independent pathways. Finally, the chondrocyte culture supernatants were collected to measure the IL-6 concentration after IL-1β stimulation and co-culture with M1 macrophages. Chondrocytes transfected with IL-6 siRNA or subjected to PBM intervention secreted less IL-6 than those transfected with only negative control siRNA under both IL-1β stimulation and macrophage co-culture conditions (Fig. 5K). PBM alleviates OA progression by regulating macrophage polarization in vivo IF staining of the F4/80 marker revealed significant macrophage depletion within the knee joint after the intra-articular administration of CLD Lips, whereas PBM intervention did not decrease the overall macrophage population (Fig. 6A). However, representative IF images of the OA + PBM group illustrated that a marked decrease in CD86+ M1 macrophage infiltration, which are associated with pro-inflammatory responses, and concurrently enhanced the abundance of CD206+ M2 macrophages, which are known for their anti-inflammatory property [46] (Fig. 6B). These findings suggested that PBM exerts its anti-inflammatory effects by facilitating a shift in M1/M2 macrophage polarization. Micro-CT images (Fig. 6C) revealed that the joint tissue surface in the sham group was intact with relatively uniform trabecular bone distribution. In contrast, the OA group and OA + CTRL Lips group showed higher bone volume fractions and lower trabecular separation. The OA + CLD Lips + PBM group exhibited a decrease in BV/TV and an increase in Tb.Sp compared to the other OA groups, indicating reduced articular cartilage injury (Fig. 6D and E). The IF staining and the representative micro-CT images of mouse knees. A The effects of CLD Lips and PBM intervention on macrophage depletion by IF staining (n = 4). F4/80 is a pan-macrophage marker (green). B The effects of CLD Lips and PBM intervention on macrophage polarization by IF staining (n = 4). CD86 is a M1 macrophage marker (green), and CD206 is a M2 macrophage marker (red). C 2D reconstruction of micro-CT images of knee joints. D BV/TV and E Tb.Sp of micro-CT analysis (n = 5). (Data are presented as mean ± SD; Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) H&E and Safranin O-Fast Green staining (Fig. 7A and B) revealed tibial plateau degeneration in the OA and OA + CTRL Lips groups, characterized by irregular cartilage surfaces, fibrocartilaginous osteophytes and synovial hyperplasia with increased lining by cell layers and mild inflammatory cell infiltration. Both these groups exhibited elevated OARSI and Mankin scores compared to the sham group (Fig. 7C and D). Intra-articular injection of CLD Lips monotherapy reduced OA progression, while the combination of CLD Lips and PBM intervention further mitigated cartilage surface roughness and reduced the proliferation of synoviocytes. The histological staining and behavioural pain assessments of mice. A H&E staining and B Safranin O-Fast Green staining of knee joint (n = 4). C OARSI score and D Mankin score of knee joint (n = 6). Hyperalgesia measured by E von frey test and F hot plate test (n = 10). (Data are presented as mean ± SD; Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) The von frey test and hot plate test demonstrated that OA model mice exhibited significant mechanical allodynia (Fig. 7E) and thermal hyperalgesia (Fig. 7F). CLD Lips monotherapy partially alleviated the mechanical allodynia, while PBM showed more pronounced effects on thermal hyperalgesia. Notably, the combination of CLD Lips and PBM intervention exhibited synergistic effects, restoring pain responses to near-normal levels and outperforming either intervention alone. The combined histological staining and behavioural pain assessments revealed that CLD Lips and PBM intervention exhibited synergistic therapeutic effects in comprehensive OA management. PBM modulates cartilage catabolism through the IL-6/JAK/STAT pathway IHC staining revealed significantly stronger staining intensities for cartilage-degrading enzymes (MMP13 and ADAMTS5) and IL-6/JAK/STAT pathway components (IL-6, JAK1, JAK2 and STAT3) in the OA and OA + CTRL Lips groups than in the other groups (Fig. 8A–L). Compared with the sham group, the combination of CLD Lips and PBM intervention most effectively reduced the expression of these markers. The expression of degrading enzymes and important molecules in the IL-6/JAK/STAT pathway by IHC. (A–D) IHC staining and quantification of MMP13 and ADAMTS5 in mice knee joint cartilages (n = 4). (E–L) IHC staining and quantification of IL-6, JAK1, JAK2, STAT3 in mice knee joint synovial tissues (n = 4). (Data are presented as mean ± SD; Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) On the basis of our previous RNA-seq analysis indicating the involvement of the IL-6/JAK/STAT pathway and macrophage activity in OA progression, we validated these findings by western blotting and qPCR analyses in animal models (Fig. 9A and G). Both the CLD-Lips and PBM intervention significantly downregulated both the protein expression and the relative mRNA expression of cartilage-degrading enzymes (MMP13 and ADAMTS5) and reduced the expression of IL-6/JAK/STAT pathway components (IL-6, JAK1, JAK2, STAT3 and p-STAT3). These results demonstrated that the PBM intervention attenuated OA progression by suppressing catabolism through the IL-6/JAK/STAT pathway. The expression of degrading enzymes and important molecules of the IL-6/JAK/STAT pathway by western blot and qPCR. A The protein expression of MMP13, ADAMTS5, IL-6, JAK1, JAK2, STAT3 and P-STAT3. β-actin was used as an internal loading control (n = 3). B The relative mRNA expression of MMP13, ADAMTS5, IL-6, JAK1, JAK2 and STAT3. GAPDH was used as a reference gene (n = 3). (Data are presented as mean ± SD; Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) Discussion In this study, PBM attenuated the catabolism of OA chondrocytes by regulating macrophage polarization and reducing joint tissue damage in OA mice. The IL-6/JAK/STAT pathway may be a key pathway through which PBM slowed down the progression of OA disease by modulating macrophage immune regulation. Local immune processes respond to joint damage, leading to chronic, slow, and low-grade inflammation involving both innate and adaptive immune regulation [47]. Promoting macrophage polarization towards the M2 phenotype and regulating the M1/M2 macrophage ratio may be crucial for suppressing local inflammation and promoting tissue regeneration [48]. Although the precise mechanisms through which immune cells mediate the immune response in joint tissues are not fully understood, our scRNA-seq data highlighted macrophages as key players in this process. Our previous studies have shown that macrophages are highly infiltrated into the OA synovium and that IL-6 could be a potential immunoregulatory target [49]. Our current bulk RNA-seq analysis also revealed that multiple signalling pathways are involved in the progression of OA, with the IL-6-mediated JAK/STAT pathway emerging as a significant pathway. Disruption of the balance between anabolic activity and catabolic activity in chondrocytes results in the loss of cartilage homeostasis and the degeneration of articular cartilage, exacerbating disease severity and progression [50, 51]. Our in vitro experiments revealed a similar pattern, with increased anabolic activity and catabolic activity during the differentiation of chondrogenic cells into chondrocytes and a shift from anabolic–catabolic homeostasis to a catabolic state during the process of chondrocyte hypertrophy. The expression of IL-6, JAK1, JAK2, STAT3 and P-STAT3, key molecules of the IL-6/JAK/STAT pathway, was consistent with the expression of degradation enzymes involved in catabolism, while anabolic markers did not show the same trend. These results indicated that the IL-6/JAK/STAT pathway is activated and involved in the catabolic process of chondrocytes. Previous studies have shown that PBM can effectively treat OA, yielding positive results in both clinical trials and animal studies [25]. PBM reduced joint tissue destruction and decreased the levels of inflammatory markers in OA disease models [34, 52]. Additionally, when PBM was combined with aquatic progressive resistance exercise, intra-articular platelet-rich plasma injection and other interventions for the treatment of OA, both the progression of the disease and the symptoms were significantly alleviated [53–55]. However, most studies focus primarily on pathologic changes and disease-related outcomes following PBM intervention, either alone or as part of a combinatory regimen, without investigating the specific cellular subpopulations affected or the underlying molecular mechanisms [56]. Our study extended these prior observations by revealing the specific anti-inflammatory effect of PBM on macrophage polarization and the subsequent crosstalk with chondrocyte catabolism through the IL-6/JAK/STAT pathway. The results of the CCK-8 cell experiments demonstrated that PBM promoted chondrocyte proliferation, whether through a single intervention or seven consecutive interventions. PBM continuous intervention also significantly slowed the hypertrophy of cells. Other studies have consistently confirmed that PBM administered at varying doses effectively reduces the population of M1 macrophages across diverse disease models [57–59]. The flow cytometry results in our study revealed that PBM could inhibit macrophage polarization toward M1 phenotype induced by LPS and IFN-γ. We found that M1 macrophage co-culture elicited the similar catabolism to that observed in the in vitro OA model induced by IL-1β. IL-6 silencing or PBM intervention significantly reduced the production of degrading enzymes under IL-1β stimulation and M1 macrophage co-culture conditions via the IL-6/JAK/STAT pathway. The combination of a JAK inhibitor and PBM synergistically suppressed IL-1β-induced chondrocyte catabolism via enhanced inhibition of the IL-6/JAK/STAT pathway, with PBM exerting additional protective effects. This has also been confirmed in other studies, which reported that PBM regulated the NF-κB signalling pathway and oxidative stress in OA [60, 61]. These mechanisms may work in synergy with the IL-6/JAK/STAT pathway, thereby achieving the observed synergistic protective effect. Macrophages are important regulators of the immune response and orchestrate both inflammatory and reparative processes [62]. In the animal model of OA induced by DMM surgery, macrophage depletion was performed using CLD Lips [63] and/or PBM intervention. Our finding demonstrated that treatment with CLD Lips reduced the number of macrophages, cartilage destruction and pain caused by OA. PBM did not directly mediate macrophage depletion but promoted a decrease in pro-inflammatory M1 macrophages and an increase in anti-inflammatory M2 macrophages. Both CLD Lips and PBM significantly improved the OARSI and Mankin scores of OA mice, reduced the pain caused by OA, and helped maintain the stability of bone trabeculae, suggesting a chondroprotective effect through the regulation of macrophage polarization. Our study also revealed that this functional improvement was mechanistically linked to the modulation of the IL-6/JAK/STAT pathway, thereby antagonizing cartilage catabolism. These findings underscore that targeting macrophage polarization is a promising therapeutic strategy for modulating the immune system in OA [64, 65]. Limitations While this study provides evidence supporting the therapeutic potential of PBM in OA through the modulation of macrophage polarization, several limitations should be acknowledged. PBM is a non-invasive, non-thermal modality with an excellent safety profile and minimal side effects, making it an attractive alternative or adjunct to pharmacological treatments [66]. Our study demonstrated the efficacy of PBM in modulating the IL-6/JAK/STAT pathway and reducing catabolic activity in chondrocytes, and we recognize that the translation of PBM dosing from cell and rodent models to human patients remains a complex challenge. The parameters used in this study, including wavelength, power density, treatment duration, and total energy delivery, were selected on the basis of established protocols in preclinical models, and were effective in achieving significant biological outcomes in our experimental setup. However, it is important to recognize that differences in tissue depth, volume, and optical properties between species can significantly influence light penetration and energy absorption. The in vitro experiments utilized murine-derived cell lines (ATDC5 chondrogenic cells and RAW264.7 macrophages) rather than primary human cells or primary mouse cells. The sample sizes were selected based on field standards and pilot data, which proved sufficient to detect the large effect sizes observed in this study. Although a formal a priori power analysis was not conducted, the robustness of the significant outcomes confirms the adequacy of the chosen group sizes. Our investigation focused primarily on the IL-6/JAK/STAT pathway, and while this pathway appears to be central to the observed effects, other signalling mechanisms may also contribute to PBM-mediated protection in OA and remain to be explored. Further clinical and basic investigations are warranted to address these constraints. Conclusion This study demonstrated that PBM alleviates OA progression by modulating macrophage polarization, attenuating cartilage degradation and synovial hyperplasia via the IL-6/JAK/STAT pathway. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements The authors acknowledge the assistance of the Translational Medicine Centre at The First Affiliated Hospital of Zhengzhou University in providing access to analytical instruments, and thank Dr. Yanru Chen, Dr. Hang Zhou, Dr. Xiangyang Wei and Dr. Yan Wang for their technical support. Abbreviations Osteoarthritis Photobiomodulation Interleukin-1β Interleukin-6 Light-emitting diodes Tumour necrosis factor-α Gene expression omnibus Foetal bovine serum Insulin-transferrin-selenium Destabilization of the medial meniscus Control liposomes Clodronate liposomes Author contributions HM.W and HW.Z designed the research and wrote the main manuscript text; J.N and SA.D conducted animal experiments, collected samples of animals and conducted laboratory experiments; WH.N and YY.L managed, analyzed and organized the data. All authors reviewed the manuscript. Funding This work was supported by the Key Science and Technology Research Project of the Education Department of Henan Province, China (grant number 242102310183); the Youth Project of the National Natural Science Foundation of China (grant number 82305400); the Health Commission Joint Project of Henan Province, China (grant number LHGJ20220352); and the Key Scientific Research Project Plan of Colleges and Universities in Henan Province, China (grant number no. 25B320004). Data availability The data underlying this article are available in Zenodo at 10.5281/zenodo.17120487. Declarations Ethics approval and consent to participate The protocols for conducting animal experiments were approved by the Ethics Committee of Zhengzhou University (ZZU-LAC20220902[09]), and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement The data underlying this article are available in Zenodo at 10.5281/zenodo.17120487.